described distribution trends of decidual immune cell populations along gestation, and identified novel behavior of cell populations, such as a unique population of invasive extra-villous trophoblasts, located within spiral artery lumens. These cells were found to express a repertoire of canonical immune markers, previously thought to be of maternal origin, suggesting a reevaluation of the role of maternal NK cells in spiral artery remodeling. CONCLUSION: MIBI technology now provides a previously-unavailable opportunity for characterization of immune activity, enabling identification of novel cell populations. Our comprehensive characterization of decidual immune cells in normal gestation is essential for delineating pathological placentation mechanisms, such as abnormal spiral artery remodeling in preeclampsia.
OBJECTIVE:
Several groups have recently demonstrated initial proofof-concept success for corrective fetal gene therapy in Gaucher's and other inborn errors of metabolism. However, a major hurdle is regulating the timing of expression of corrective genes to coincide with normal embryonic development windows. We hypothesized that use of an AFP enhancer element tied to a conditional transgene would allow for fetal gene activation concordant with normal expression of AFP in the fetal liver. Specifically, we developed a novel conditional knock out (cKO) mouse model deleting Npas2 in the neonatal liver (neonatal Npas2 cKO). By genetically engineering this cKO transgene with a 3' AFP enhancer, the loss of Npas2 occurred during fetal development (fetal Npas2 cKO). Utilizing these two Npas2 cKO models we were able to interrogate how the developmental timing of the loss of Npas2 resulted in distinct metabolic phenotypes. STUDY DESIGN: Npas2 cKO in the liver was achieved using a CreLox deletion strategy with Cre expression regulated by an ALB promoter ( Figure 1A ) or additionally with an AFP ( Figure 1B ) for targeted deletion of Npas2 exon 3. PCR amplification of cDNA, qPCR, and RNA in situ hybridization (RNAish) were employed to assess targeted deletion of Npas2 exon 3 mRNA. RESULTS: PCR amplification of cDNA from the mouse tissues showed that in both neonatal and fetal Npas2 cKO, exon3 was deleted (Figure 2A ) in the liver only. No changes in Npas2 mRNA transcript levels detected in both Npas2 cKO mice by qPCR and RNAish (Figure 2 B-C). CONCLUSION: We successfully generated two novel Npas2 cKO mouse models differing only by the developmental timing of gene deletion. Npas2 loss in the liver resulted in an altered metabolic phenotype of increased weight gain and body fat. Fetal Npas2 cKO mice have a reduced glucose tolerance, not observed in neonatal Npas2 cKO mice. Our approach to creating this cKO mouse model resulted in the targeted deletion of a critical region of the Npas2 mRNA, but importantly allowed for an otherwise full length transcript. With the imminent advances in fetal gene therapy, understanding how to activate transcription during fetal specific stages may allow for improved success for this in utero fetal approach. We provide here evidence of one such novel approach using an AFP enhancer.
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We have demonstrated that tadalafil facilitates fetal growth in mice with L-NG-nitroarginine methyl ester (L-NAME)-induced preeclampsia (PE) with fetal growth restriction (FGR). Tadalafil is a selective phosphodiesterase 5 inhibitor that dilates the maternal blood sinuses in the placenta, thereby facilitating the growth of the fetus. The purpose of this study was to investigate the effects of tadalafil treatment for PE and FGR on the developing brain in FGR offspring using an L-NAME-induced mouse model of PE with FGR. STUDY DESIGN: A control group of dams received carboxymethylcellulose (CMC). (C dams, n¼5) L-NAME-administered groups received L-NAME dissolved in CMC from 11 d.p.c. The L-NAMEtreated dams were divided into two subgroups 14 d.p.c. One subgroup continued to administer L-NAME. (L dams, n¼8) The other subgroup administered L-NAME with tadalafil suspended in CMC. (TL dams, n¼5) The dams were sacrificed 17 d.p.c. Placenta and fetal brain were collected. Another set of dams (C dams, n ¼ 4; L dams, n ¼ 5; TL dams, n ¼ 6) was prepared as described above, and the dams were allowed to deliver spontaneously. After delivery, all dams were given normal drinking water during lactation. The pups were sacrificed on postnatal day 15(P15) or P30 and their brains were collected. The hypoxic conditions in the placenta and in the fetal brain were assessed by the expression of hypoxia-inducible factor (HIF)-2. The brains of pups on P15 or P30 were assessed by glial fibrillary acidic protein (GFAP) expression in the corpus callosum, myelin basic protein (MBP) expression in the cingulum, and synaptophysin expression in the hippocampus. RESULTS: Tadalafil treatment for PE with FGR reduced the expression of HIF-2 in the placenta and in the brain of the FGR fetus. Moreover, tadalafil treatment in utero shows improved synaptogenesis and myelination in FGR offspring on P15 and P30. (The MBP positive area on P15 (C offspring, 7.7 AE 2.2%; L offspring, 1.3 AE 0.4%; TL offspring, 5.0 AE 0.4%) and P30 (C offspring, 20.1 AE 3.5%; L offspring, 4.8 AE 0.5%; TL offspring, 9.6 AE 0.5%), The synaptophysin positive area on P15 (C offspring, 13.8 AE 3.3%; L offspring, 5.1 AE 1.6%; TL offspring, 9.9 AE 1.7%) and P30 (C offspring, 46.2 AE 1.9%; L offspring, 8.8 AE 1.7%; TL offspring, 27.5 AE 4.6%)). CONCLUSION: These results suggest that tadalafil treatment for PE with FGR not only facilitates fetal growth, but also has neuroprotective effects on the developing brain of FGR offspring through modulating prenatal hypoxic conditions. 37 Does in utero exposure to polybrominated diphenyl ethers affect neurodevelopment?
Sevan Vahanian, Morgan Peltier NYU Winthrop Hospital, Mineola, NY OBJECTIVE: Polybrominated diphenyl ethers (PBDEs) have been widely used as flame retardants and are ubiquitous environmental toxins, detectible at some level in w100% of women. Prior studies have suggested that PBDEs enhance placental inflammation, a known risk factor for neurodevelopmental disorders like autism. Therefore, our objective was to determine if in utero exposure to PBDE results in autism-like behaviors in offspring in an inflammation-dependent manner. STUDY DESIGN: An IACAC-approved 2 x 2 factorial study design was implemented. Pregnant Wistar rats were assigned to one of 4 groups: control (VEH) without LPS, VEH with LPS, PBDE-209 without LPS, and PBDE-209 with LPS. Rats were received on gestational day (GD)3 and treated daily with cornflakes containing either PBDE-209 (1 mg/kg in corn oil) or VEH (corn oil alone) until delivery (GD23-24). On GD9, half of the dams of each group received LPS (100 mcg/kg intraperitoneally) or an equivalent volume of sterile saline (PBS). Pups from each litter underwent behavioral testing (open field and novel object) at postnatal day (PND)30 or PND60. Entries into center vs peripheral regions of the open field and interactions with or time spent with the novel object were recorded. Data was analyzed with generalized estimating equations. P < 0.05 was considered statistically significant. RESULTS: Of 24 dams, 17 of them delivered 162 pups. LPS-treated dams weighed less at GD16 than PBS-treated dams (P¼0.009). LPS and PBDE reduced PND9 pup weights (P¼0.018). For open field testing, there were no significant differences at PND30 for time spent in peripheral regions, entries into peripheral regions, time spent in center regions, or entries into center regions. At PND60, LPS increased entries into central regions but PBDE reduced the number of entries (P¼0.03) in LPS-treated rats. Between 78e100% of pups interacted with the novel object, more at PND60. Of the pups interacting with the novel object, PBDE exposure reduced the time to first encounter (P¼0.03). CONCLUSION: In utero exposure to LPS, PBDE-209, or both did not cause the expected autism-like behaviors in the offspring. However, PBDEtreatment significantly reduced the weights of the pups of LPS-treated dams, suggesting some adverse effects on pregnancy outcome.
